Skip to Main Content

When Donald Trump’s lawyer, Michael Cohen, approached Novartis early last year to provide access to the new Trump administration, the company’s response was tone-deaf. But it was hardly a surprise.

The personal lawyer and “fixer” for the president came knocking as big drug makers were anxious about the future, since candidate Trump had lambasted them for through-the-roof prices. So former Novartis chief executive Joe Jimenez quickly authorized a one-year, $1.2 million deal. This was considerably more than Novartis typically paid Washington lobbyists. And it wasn’t for Cohen’s policy expertise — he knew nothing about health care.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • USA: the masters in the art of bribing

    It is amusing how what around the world is called bribing, in the US is called lobbying and gaining insights or access

Comments are closed.